Good news for those of us who can’t face the day without their morning flat white: a long-term study has revealed drinking higher amounts of coffee may make you less likely to develop Alzheimer’s disease.
As part of the Australian Imaging, Biomarkers and Lifestyle Study of ageing, researchers from Edith Cowan University (ECU) investigated whether coffee intake affected the rate of cognitive decline of more than 200 Australians over a decade.
Lead investigator Dr. Samantha Gardener said results showed an association between coffee and several important markers related to Alzheimer’s disease.
“We found participants with no memory impairments and with higher coffee consumption at the start of the study had lower risk of transitioning to mild cognitive impairment — which often precedes Alzheimer’s disease — or developing Alzheimer’s disease over the course of the study,” she said.
New highly sensitive quantum sensors for the brain may in the future be able to identify brain diseases such as dementia, ALS and Parkinson’s, by spotting a slowing in the speed at which signals travel across the brain. The research findings from a paper led by University of Sussex quantum physicists are published in Scientific Reports journal.
The quantum scanners being developed by the scientists can detect the magnetic fields generated when neurons fire. Measuring moment-to-moment changes in the brain, they track the speed at which signals move across the brain. This time-element is important because it means a patient could be scanned twice several months apart to check whether the activity in their brain is slowing down. Such slowing can be a sign of Alzheimer’s or other diseases of the brain.
In this way, the technology introduces a new method to spot bio-markers of early health problems.
Aikaterini Gialopsou, a doctoral researcher in the School of Mathematical and Physical Sciences at the University of Sussex and Brighton and Sussex Medical School is the lead author on the paper. She says of the discovery:
“We’ve shown for the first time that quantum sensors can produce highly accurate results in terms of both space and time. While other teams have shown the benefits in terms of locating signals in the brain, this is the first time that quantum sensors have proved to be so accurate in terms of the timing of signals too.
The drop in estrogen levels that occurs with menopause brings declines in the volumes of “gray matter,” the cellular matter of the brain, in key brain regions that are also affected in Alzheimer’s disease. But a new study from Weill Cornell Medicine researchers, in collaboration with the University of Arizona, suggests that greater cumulative exposure to estrogen in life, for example from having had more children or from having taken menopause hormone therapy, may counter this brain-shrinking effect.
The findings, reported Nov. 3 in Neurology, come from an analysis of personal histories, MRI scans and cognitive tests on 99 women in their late 40s to late 50s. The researchers confirmed an earlier finding linking menopause to lower gray matter volume (GMV) in brain areas that are vulnerable to Alzheimer’s. But they also linked indicators of higher overall estrogen exposure, such as a longer span of reproductive years (menarche to menopause), more children and the use of menopause hormone therapy and hormonal contraceptives, to higher GMV in some of these brain areas.
Working with their colleagues at the University of Pennsylvania, researchers at the University of Kentucky have found that they can differentiate between sub-types of dementia inducing brain disease.
“For the first time we created criteria that could differentiate between frontotemporal dementia (FTD) and a common Alzheimer’s ‘mimic’ called LATE disease,” said Dr. Peter Nelson of the Sanders-Brown Center on Aging at the University of Kentucky. He says they validated the criteria rigorously. The study was recently published in BRAIN: A Journal of Neurology. The first author of the paper was John L. Robinson from the University of Pennsylvania and the corresponding author was Nelson.
A new blood test demonstrated remarkable promise in discriminating between persons with and without Alzheimer’s disease and in persons at known genetic risk may be able to detect the disease as early as 20 years before the onset of cognitive impairment, according to a large international study published in the Journal of the American Medical Association (JAMA) and simultaneously presented at the Alzheimer’s Association International Conference.
For many years, the diagnosis of Alzheimer’s has been based on the characterization of amyloid plaques and tau tangles in the brain, typically after a person dies. An inexpensive and widely available blood test for the presence of plaques and tangles would have a profound impact on Alzheimer’s research and care. According to the new study, measurements of phospho-tau217 (p-tau217), one of the tau proteins found in tangles, could provide a relatively sensitive and accurate indicator of both plaques and tangles — corresponding to the diagnosis of Alzheimer’s — in living people. Continue reading →
Cognitive decline is a major concern of the aging population. Already, Alzheimer’s disease affects approximately 5.4 million Americans and 30 million people globally. Without effective prevention and treatment, the prospects for the future are bleak. By 2050, it is estimated that 160 million people globally will have the disease, including 13 million Americans, leading to potential bankruptcy of the Medicare system. Unlike several other chronic illnesses, Alzheimer’s disease is on the rise–recent estimates suggest that Alzheimer’s disease has become the third leading cause of death in the United States behind cardiovascular disease and cancer. Since its first description over 100 years ago, Alzheimer’s disease has been without effective treatment.
While researchers continue to seek out a cure, it is becoming clear that there are effective treatment options. More and more research supports the conclusion that Alzheimer’s disease is not a disease of only Beta Amyloid plaques and Tao tangles but a complex and systemic disease. In this study of patients with varying levels of cognitive decline, it is demonstrated how a precision and personalized approach results in either stabilization or improvement in memory.
Affirmativ Health sought to determine whether a comprehensive and personalized program, designed to mitigate risk factors of Alzheimer’s disease could improve cognitive and metabolic function in individuals experiencing cognitive decline. Findings provided evidence that this approach can improve risk factor scores and stabilize cognitive function.
Do you know that feeling you get in your gut? It turns out your gut may really be trying to tell you something. Our microbiome – the 100 trillion bacteria and organisms living in our gut – appears to have a profound influence on our health and risk of disease. And early scientific studies show there may be a link between the microbiome and the brain that could impact the risk of Alzheimer’s and other brain diseases.
The microbiome is a collection of bacteria, viruses and fungi that live mostly in our intestinal system. They play an important role in digestion and the production of certain vitamins, and they support our immune system. Researchers around the world study the gut microbiome, especially those bacteria unique to individuals, to learn more about their influence on our overall health.
Alzheimer’s disease is a progressive disorder in which the nerve cells (neurons) in a person’s brain and the connections among them degenerate slowly, causing severe memory loss, intellectual deficiencies, and deterioration in motor skills and communication. One of the main causes of Alzheimer’s is the accumulation of a protein called amyloid β (Aβ) in clusters around neurons in the brain, which hampers their activity and triggers their degeneration.
Studies in animal models have found that increasing the aggregation of Aβ in the hippocampus–the brain’s main learning and memory center–causes a decline in the signal transmission potential of the neurons therein. This degeneration affects a specific trait of the neurons, called “synaptic plasticity,” which is the ability of synapses (the site of signal exchange between neurons) to adapt to an increase or decrease in signaling activity over time. Synaptic plasticity is crucial to the development of learning and cognitive functions in the hippocampus. Thus, Aβ and its role in causing cognitive memory and deficits have been the focus of most research aimed at finding treatments for Alzheimer’s.
Researchers have found a way to design an antibody that can identify the toxic particles that destroy healthy brain cells – a potential advance in the fight against Alzheimer’s disease.
Their method is able to recognize these toxic particles, known as amyloid-beta oligomers, which are the hallmark of the disease, leading to hope that new diagnostic methods can be developed for Alzheimer’s disease and other forms of dementia.
The team, from the University of Cambridge, University College London and Lund University, designed an antibody which is highly accurate at detecting toxic oligomers and quantifying their numbers. Their results are reported in the Proceedings of the National Academy of Sciences (PNAS).
Older adults who have surgery with general anesthesia may experience a modest acceleration of cognitive decline, even years later. But there’s no evidence of a link to Alzheimer’s disease, according to new research from Mayo Clinic.
The research, published in the British Journal of Anaesthesia, examined brain scans from 585 patients, ages 70 to 91 ― 493 of whom had at least one surgery with general anesthesia. The analysis found cortical thinning in cerebral areas but no significant evidence of deposits of amyloid protein, a hallmark of Alzheimer’s disease. The cortex is the outermost layer of the brain’s nerve cell tissue, and thinning of that tissue is associated with diminished cognitive functions. Continue reading →
Inflammation in the brain may be more widely implicated in dementias than was previously thought, suggests new research from the University of Cambridge. The researchers say it offers hope for potential new treatments for several types of dementia.
Inflammation is usually the body’s response to injury and stress – such as the redness and swelling that accompanies an injury or infection. However, inflammation in the brain – known as neuroinflammation – has been recognized and linked to many disorders including depression, psychosis and multiple sclerosis. It has also recently been linked to the risk of Alzheimer’s disease.
In a study published in the journal Brain, a team of researchers at the University of Cambridge set out to examine whether neuroinflammation also occurs in other forms of dementia, which would imply that it is common to many neurodegenerative diseases.
Herewith another entry in our arsenal against that destroyer of lives – Alzheimer’s Disease, from the Tufts Health & Nutrition Letter.
Alzheimer’s disease accounts for 60 to 80 percent of the loss of memory and other cognitive abilities collectively known as dementia. There is no known food or diet that can prevent or cure Alzheimer’s dementia, but diet may help delay onset and slow progression.
What sets Alzheimer’s apart from other forms of dementia is the excessive buildup of beta-amyloid protein fragments into plaques, as well as defective tau proteins that form tangles in the brain. These changes lead to the death of the nerve cells responsible for everything from memory to movement. There are currently no known dietary factors that can impact the formation of these plaques and tangles, but diet may act in other ways to influence Alzheimer’s and other forms of dementia.
Being a senior citizen with a family tree containing both Alzheimer’s Disease and dementia, I read everything I can on the subject. Here is the latest from the Global Council on Brain Health (GCBH).
Did you know that taking care of your heart can reduce your risk for memory and thinking problems? A review of medical research conducted by the Global Council on Brain Health recently showed a reduced risk of dementia with improved heart health. So, let’s review their major findings to learn how we can take better care of our hearts and brains. Continue reading →
While there is no known ‘silver bullet’ for Alzheimer’s disease it appears that there may be some ‘luck of the draw’ genetic variants that help.
A DNA study of over 10,000 people by University College of London (UCL) scientists has identified a class of gene variants that appear to protect against Alzheimer’s disease.
The findings, published in Annals of Human Genetics, suggest these naturally occurring gene variants reduce the functioning of proteins called tyrosine phosphatases, which are known to impair the activity of a cell signalling pathway known as PI3K/Akt/GSK-3β. This pathway is important for cell survival.
The research builds on previous studies in mice and rats, which suggested inhibiting the function of these proteins might be protective against Alzheimer’s disease, but this is the first time such an effect has been demonstrated in people.
Researchers believe the PI3K/Akt/GSK-3β signalling pathway could be a key target for therapeutic drugs and the findings also strengthen evidence that other genes could be linked to either elevated or reduced risk of Alzheimer’s disease.
“These results are quite encouraging. It looks as though when naturally-occurring genetic variants reduce the activity of tyrosine phosphatases then this makes Alzheimer’s disease less likely to develop, suggesting that drugs which have the same effect might also be protective,” said the study’s lead author, Professor David Curtis (UCL Genetics Institute).
As a senior citizen whose family has Alzheimer’s Disease and other forms of dementia on both sides, I take these studies very seriously
Living near major roads or highways is linked to higher incidence of dementia, Parkinson’s disease, Alzheimer’s disease and multiple sclerosis (MS), suggests new research published this week in the journal Environmental Health.
Researchers from the University of British Columbia analyzed data for 678,000 adults in Metro Vancouver. They found that living less than 50 meters from a major road or less than 150 meters from a highway is associated with a higher risk of developing dementia, Parkinson’s, Alzheimer’s and MS—likely due to increased exposure to air pollution.
The researchers also found that living near green spaces, like parks, has protective effects against developing these neurological disorders.
I have written repeatedly about getting a good night’s sleep. You can check my page – How important is a good night’s sleep? for more details. Regular readers also know about my concern about cognition and the vulnerability of an aging brain because of the Alzheimer’s Disease and dementia in my family.
A preliminary study by researchers at Uppsala University has found that when young, healthy men were deprived of just one night of sleep, they had higher levels of tau – a biomarker for Alzheimer’s disease – in their blood than when they had a full, uninterrupted night of rest. The study is published in the medical journal Neurology.
Tau is a protein found in neurons and the protein can form into tangles. These accumulate in the brains of people with Alzheimer’s disease. This accumulation can start decades before symptoms of the disease appear. Previous studies of older adults have suggested that sleep deprivation can increase the level of tau in the cerebral spinal fluid. Trauma to the head can also increase circulating concentrations of tau in blood.